In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is ‘fully human’, T cell epitopes that are contained in the sequences of the biologic may activate the i...
Saved in:
| Main Authors: | Aimee E. Mattei, Andres H. Gutierrez, Soorya Seshadri, Jacob Tivin, Matt Ardito, Amy S. Rosenberg, William D. Martin, Anne S. De Groot |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2333729 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine
by: Kirk Haltaufderhyde, et al.
Published: (2025-12-01) -
Immunogenicity induced by biologicals in the treatment of psoriasis and psoriatic arthritis: View of the problem
by: T. V. Korotaeva
Published: (2016-01-01) -
Identification of B-cell epitopes of Indian Zika virus strains using immunoinformatics
by: Rohan Raj Roy, et al.
Published: (2025-02-01) -
Immunogenicity risk assessment for tailored mitigation and monitoring of biotherapeutics during development: recommendations from the European Immunogenicity Platform
by: Joanna Grudzinska-Goebel, et al.
Published: (2025-05-01) -
Monoclonal antibodies against Mycobacterium tuberculosis, detecting the antigen in urine of the pulmonary tuberculosis patients
by: A. V. Onyan, et al.
Published: (2016-02-01)